Gardasil may not be cost-effective for boys

October 9, 2009 9:12:08 AM PDT
Vaccinating boys against the human papillomavirus does not appear to be cost-effective. The Food and Drug Administration is weighing whether to approve Gardasil for use in males ages 9 to 26 to protect them from genital warts.

The Centers for Disease Control and Prevention recommends the shot for females ages 11 to 26.

Merck, the company which makes Gardasil, is now seeking approval for use in boys and men.

Government researchers say clinical trials show that the vaccine offers a high degree of protection, but might not be worth the cost of routine vaccinations for males.


Load Comments